AL amyloidosis of the kidney Medical Services in China

AL amyloidosis of the kidney is a rare, systemic plasma cell disorder characterized by the deposition of monoclonal immunoglobulin light chains (predominantly lambda) as insoluble, β-pleated sheet amyloid fibrils in renal tissue. These deposits disrupt normal glomerular and tubulointerstitial architecture, leading to progressive proteinuria, nephrotic syndrome, and ultimately end-stage kidney disease if untreated. Pathogenesis begins with clonal expansion of bone marrow plasma cells producing misfolded, aggregation-prone light chains. Unlike multiple myeloma, the plasma cell burden is typically low (<10% in bone marrow), but the secreted light chains are inherently unstable and prone to proteolytic cleavage and fibril formation. Once deposited in the kidney—especially in glomeruli, blood vessels, and interstitium—they trigger chronic inflammation, podocyte injury, endothelial dysfunction, and capillary basement membrane thickening. Epidemiologically, AL amyloidosis affects approximately 8–12 per million people annually worldwide; renal involvement occurs in over 70% of cases at diagnosis, making it the most common organ manifestation. It predominantly affects adults aged 60–75 years, with a slight male predominance (male:female ≈ 1.3:1). Risk factors include advancing age, undiagnosed monoclonal gammopathy of undetermined significance (MGUS), chronic inflammatory conditions, and genetic polymorphisms in genes involved in protein folding and clearance (e.g., SERPINA1, RBP4). Notably, no strong environmental or lifestyle risk factors have been established. Quality of life is profoundly impacted: patients frequently experience debilitating fatigue, edema-related mobility limitations, recurrent infections due to hypoalbuminemia and immunosuppression, anxiety surrounding rapid functional decline, and psychosocial strain from diagnostic delays (median time to diagnosis is 6–12 months). Renal impairment correlates strongly with reduced physical functioning, depression prevalence (up to 40%), and diminished health-related quality of life scores on validated instruments like KDQOL-SF. Early recognition—through serum free light chain assay, 24-hour urine protein electrophoresis, and kidney biopsy with Congo red staining and mass spectrometry confirmation—is critical. Without treatment, median survival after renal involvement is <2 years; with modern risk-adapted therapy, 5-year survival exceeds 60%. However, persistent proteinuria and declining eGFR remain major drivers of long-term morbidity, dialysis dependence, and transplant eligibility challenges.

AL (amyloid light-chain) amyloidosis of the kidney is a systemic plasma cell dyscrasia characterized by the deposition of misfolded monoclonal immunoglobulin light chains—predominantly lambda (κ:λ ratio ~1:2)—as insoluble extracellular fibrils in renal tissue. The primary cause is clonal expansion of bone marrow plasma cells producing structurally unstable, protease-resistant light chains that undergo conformational change, aggregate into β-pleated sheet-rich fibrils, and deposit in glomeruli, vessels, and interstitium. These deposits disrupt normal architecture and function, leading to proteinuria (often nephrotic-range), progressive decline in glomerular filtration rate (GFR), and eventual end-stage kidney disease if untreated.

Triggers are not fully elucidated but often involve chronic antigenic stimulation or immune dysregulation that promotes plasma cell survival and aberrant light chain production. Infections (e.g., chronic hepatitis C, HIV), autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), and persistent inflammatory states may act as precipitants in susceptible individuals by fostering a pro-survival microenvironment for abnormal plasma cells. Additionally, treatment-related stressors—including prior chemotherapy or stem cell transplantation—can unmask or accelerate underlying clonal disease in some cases.

Established risk factors include advanced age (median diagnosis at 65–70 years), male sex (male-to-female ratio ~2:1), and preexisting monoclonal gammopathy of undetermined significance (MGUS), which precedes AL amyloidosis in ~15–20% of cases. Patients with multiple myeloma have a 10–15% lifetime risk of developing AL amyloidosis; conversely, up to 10% of newly diagnosed AL amyloidosis patients harbor coexistent myeloma. Other hematologic risk conditions include Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. Renal involvement is nearly universal in systemic AL amyloidosis (≥95% of patients), with heavy proteinuria (>3.5 g/day) and elevated serum free light chain (sFLC) difference (dFLC ≥ 180 mg/L) strongly correlating with severity and progression.

Genetic factors play a modulatory rather than deterministic role. No high-penetrance germline mutations cause AL amyloidosis, but polymorphisms in genes involved in protein folding, degradation, and immune regulation influence susceptibility and phenotype. Notably, the immunoglobulin light chain variable region (IGLV) gene usage is nonrandom: >70% of AL cases use IGLV6-57 (formerly 6a) or IGLV3-19, with specific somatic hypermutation patterns conferring thermodynamic instability and amyloidogenic propensity. Germline variants in *APOE* (ε4 allele) may modestly increase amyloid deposition burden, while polymorphisms in *SERPINA1* (encoding α1-antitrypsin) and *HSPG2* (perlecan) have been associated with altered fibril persistence and organ tropism. Familial aggregation is rare but reported, suggesting polygenic inheritance interacting with acquired somatic events.

Environmental exposures are not direct causes but may contribute to immune dysregulation and clonal selection. Chronic occupational exposure to agricultural chemicals (e.g., pesticides, herbicides) and industrial solvents has shown weak epidemiologic associations in cohort studies, though causality remains unproven. Smoking is linked to increased risk of MGUS and may promote plasma cell clonality via oxidative stress and NF-κB activation. Obesity and metabolic syndrome correlate with higher sFLC levels and worse renal outcomes, likely through chronic low-grade inflammation and adipokine-mediated B-cell modulation. Importantly, no infectious agent directly produces amyloid fibrils; however, persistent viral antigens (e.g., EBV latent membrane proteins) may provide chronic B-cell receptor stimulation, facilitating emergence of amyloidogenic clones. Geographic and socioeconomic disparities exist—underdiagnosis is common in resource-limited settings due to lack of serum/urine immunofixation, sFLC assays, and tissue Congo red staining with polarized microscopy—underscoring that diagnostic access itself functions as an indirect environmental risk factor for delayed intervention and irreversible renal damage.

AL amyloidosis of the kidney is a systemic plasma cell dyscrasia characterized by the deposition of monoclonal immunoglobulin light chains (predominantly lambda) as insoluble, β-pleated sheet fibrils in renal tissue—particularly the glomeruli, vasculature, and interstitium. As the most common cause of nephrotic syndrome in adults over age 60, renal involvement occurs in >70% of patients with systemic AL amyloidosis and often represents the initial or dominant clinical manifestation. Early symptoms are frequently subtle and nonspecific, reflecting progressive glomerular injury before overt proteinuria or edema develops. Patients may report unexplained fatigue, mild weight gain, or intermittent lower extremity swelling that is initially attributed to aging, venous insufficiency, or medication side effects (e.g., calcium channel blockers). A gradual decline in exercise tolerance, orthostatic lightheadedness, or new-onset nocturia may reflect early volume overload or subtle reductions in glomerular filtration rate (GFR). Importantly, hypertension is notably absent or only mildly elevated in most cases—distinguishing AL amyloidosis from other glomerulopathies such as diabetic nephropathy or focal segmental glomerulosclerosis—due to the lack of significant vascular remodeling or renin-angiotensin activation. Serum creatinine may remain normal or near-normal despite substantial structural damage, underscoring the insensitivity of serum creatinine as an early biomarker.

Typical symptoms emerge as glomerular filtration barrier integrity deteriorates. Nephrotic-range proteinuria (>3.5 g/24 h) is present in >90% of patients at diagnosis and is often massive (≥10 g/24 h), driven primarily by albumin loss. This leads to hypoalbuminemia (<3.0 g/dL), which manifests clinically as generalized edema—most prominently periorbital in the morning and dependent (ankles, sacrum) later in the day—and occasionally ascites or pleural effusions in advanced cases. Hyperlipidemia (elevated total cholesterol, LDL, and triglycerides) is nearly universal due to hepatic upregulation of lipoprotein synthesis in response to hypoalbuminemia. Patients may also experience frothy urine, a subjective but highly suggestive sign of severe proteinuria. Renal dysfunction progresses variably: while some retain stable GFR for months to years, others develop rapidly worsening azotemia, with serum creatinine doubling within weeks—a pattern termed 'rapidly progressive renal failure'—often associated with concurrent cardiac or hepatic amyloid burden. Microscopic hematuria is uncommon (<20% of cases) and typically bland (no dysmorphic RBCs or RBC casts), reflecting non-inflammatory capillary wall disruption rather than crescentic or proliferative glomerulonephritis.

Accompanying symptoms reflect multisystem involvement and should prompt systematic evaluation. Cardiac manifestations—including exertional dyspnea, orthopnea, palpitations, and reduced exercise capacity—are present in ~50% of patients with renal AL amyloidosis and significantly worsen prognosis. Peripheral neuropathy (distal symmetric sensorimotor or autonomic) may manifest as numbness, tingling, orthostatic hypotension, or gastrointestinal dysmotility (early satiety, constipation, diarrhea). Hepatomegaly (often painless and firm) occurs in ~30%, while macroglossia (enlarged, stiff tongue with scalloped borders) is highly specific though less frequent (~10%). Purpura—especially periorbital ('raccoon eyes')—results from vascular fragility due to amyloid infiltration of dermal vessels. Carpal tunnel syndrome, often bilateral and refractory, may precede renal diagnosis by years. Fatigue, unintentional weight loss, and recurrent infections (due to loss of immunoglobulins and complement factors in urine) are common systemic features.

Complications arise from both direct organ toxicity and secondary pathophysiology. Thromboembolism is a leading cause of morbidity and mortality: nephrotic syndrome induces a hypercoagulable state via urinary loss of antithrombin III, protein S, and plasminogen, coupled with hepatic overproduction of fibrinogen and factor VIII. Venous thromboembolism (deep vein thrombosis, pulmonary embolism) occurs in 20–40% of patients, and renal vein thrombosis may accelerate renal failure. Progressive chronic kidney disease culminates in end-stage renal disease (ESRD) requiring dialysis in ~25% within 2 years without effective therapy. Infections—including spontaneous bacterial peritonitis, pneumonia, and sepsis—are frequent due to immunoglobulin loss and impaired opsonization. Cardiac amyloidosis may precipitate heart failure, arrhythmias (especially atrial fibrillation), or sudden cardiac death. Autonomic neuropathy contributes to malnutrition, falls, and syncope. Amyloid-related renal infarction or cortical necrosis is rare but catastrophic.

Diagnosis requires integration of clinical suspicion, laboratory findings, histopathology, and clonality assessment. Urinalysis reveals heavy proteinuria (often 4+ on dipstick) with minimal or no hematuria. Serum studies show low albumin, elevated total protein (due to monoclonal gammopathy), and abnormal free light chain (FLC) ratio (involved/uninvolved FLC ratio >100 or <0.01). Serum protein electrophoresis (SPEP) and immunofixation (IFE) detect monoclonal proteins in ~75% of cases; bone marrow biopsy with immunohistochemistry and flow cytometry confirms clonal plasma cells (typically <10% but sufficient for amyloid production). Definitive diagnosis hinges on tissue biopsy: renal biopsy remains gold standard, demonstrating Congo red–positive, apple-green birefringent deposits under polarized light, with characteristic non-branching 7–10 nm fibrils on electron microscopy. Immunohistochemistry or mass spectrometry-based proteomics (e.g., laser microdissection with liquid chromatography–tandem mass spectrometry) is mandatory to confirm light-chain restriction and exclude other amyloid types (e.g., AA, ATTR). Cardiac imaging (echocardiography with strain analysis, cardiac MRI with late gadolinium enhancement, or bone scintigraphy with 99mTc-DPD/PYP/HMDP) evaluates for concomitant cardiac involvement, which critically informs treatment eligibility and prognosis.

Differential diagnosis includes other causes of nephrotic syndrome and amyloidosis. Primary glomerular diseases—minimal change disease (MCD), membranous nephropathy (MN), and focal segmental glomerulosclerosis (FSGS)—must be distinguished: MCD shows normal-appearing glomeruli on light microscopy but foot process effacement on EM; MN exhibits subepithelial immune complex deposits and anti-PLA2R antibodies; FSGS demonstrates segmental sclerosis and hyalinosis. Secondary causes include diabetes mellitus (with retinopathy, neuropathy, and characteristic nodular glomerulosclerosis), lupus nephritis (with serologic markers, immune complex deposits, and extrarenal manifestations), and hepatitis B/C–associated membranoproliferative GN. Non-AL amyloidoses require exclusion: AA amyloidosis (associated with chronic inflammation/infection, positive serum amyloid A, negative FLC assay) and hereditary or wild-type ATTR amyloidosis (negative monoclonal protein, positive TTR staining or genetic testing, absence of plasma cell dyscrasia). Light-chain deposition disease (LCDD) mimics AL amyloidosis clinically but shows granular, non-fibrillar, κ-restricted deposits on EM and lacks Congo red positivity. Finally, myeloma cast nephropathy presents with acute kidney injury, tubular casts containing monoclonal light chains, and often hypercalcemia or bone lesions—distinguishing it from the predominantly glomerular, chronic presentation of AL amyloidosis.

AL amyloidosis of the kidney is a systemic plasma cell dyscrasia characterized by the deposition of monoclonal immunoglobulin light chains (predominantly lambda) as insoluble, β-pleated sheet fibrils in renal tissue—particularly the glomeruli, interstitium, and vasculature. This leads to progressive proteinuria, nephrotic syndrome, declining glomerular filtration rate (GFR), and, if untreated, end-stage kidney disease (ESKD). Management requires a multidisciplinary approach coordinated by nephrology, hematology/oncology, cardiology, and pathology, with early diagnosis—confirmed via kidney biopsy with Congo red staining and mass spectrometry-based typing—being critical to prognosis.

Conservative treatment forms the essential supportive backbone of care. Strict blood pressure control (<130/80 mmHg) using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) is first-line to reduce intraglomerular pressure and attenuate proteinuria; however, these agents must be titrated cautiously in patients with reduced renal perfusion or hyperkalemia. Sodium restriction (<2 g/day) and fluid management are vital to mitigate edema and prevent volume overload, especially in those with concomitant cardiac amyloidosis. Diuretic therapy—typically loop diuretics (e.g., furosemide or torsemide), often combined with thiazide-like agents (e.g., metolazone) for synergistic effect—is employed judiciously to avoid prerenal azotemia. Nutritional support includes moderate protein intake (0.8–1.0 g/kg/day) to balance nitrogen requirements without exacerbating proteinuria or uremic toxicity; excessive protein restriction is discouraged due to risks of malnutrition and sarcopenia. Lipid-lowering therapy (e.g., high-intensity statins) addresses dyslipidemia common in nephrotic syndrome, while prophylactic anticoagulation may be considered in patients with serum albumin <2.5 g/dL and additional thrombotic risk factors, given the hypercoagulable state associated with AL amyloidosis.

Pharmacologic therapy targets the underlying clonal plasma cell disorder to halt production of pathogenic light chains. First-line regimens include bortezomib-based combinations: CyBorD (cyclophosphamide, bortezomib, dexamethasone) remains the most widely validated induction regimen, achieving hematologic response in ~70% of patients and renal response in ~40–50% at 6 months. Daratumumab—anti-CD38 monoclonal antibody—has revolutionized treatment; Dara-CyBorD demonstrates superior depth and speed of response, with ≥VGPR (very good partial response) rates exceeding 85% and significantly improved renal response kinetics. For transplant-ineligible patients or those with high-risk cytogenetics, daratumumab monotherapy or daratumumab–lenalidomide–dexamethasone (DRd) offer effective alternatives. Autologous stem cell transplantation (ASCT) remains an option for select patients aged <65 years with adequate cardiac function (NT-proBNP <3,300 ng/L, troponin T <0.06 ng/mL, no significant low-voltage QRS on ECG), achieving durable hematologic remission in >60% but carries substantial peri-transplant mortality risk (~5–10%) in amyloid cohorts. Novel agents under investigation include venetoclax (for t(11;14)-positive cases), bispecific antibodies, and anti-fibril monoclonal antibodies (e.g., NI006), though none are yet standard-of-care.

Surgical intervention has a highly limited role. Kidney transplantation is not contraindicated per se but is reserved exclusively for patients achieving sustained, deep hematologic response (≥CR for ≥6 months) with stable organ function and no evidence of active systemic amyloid deposition. Graft survival is comparable to non-amyloid recipients when stringent selection criteria are applied; however, recurrence—though rare (<5% at 5 years)—can occur if minimal residual disease persists. Combined heart-kidney transplantation is exceptionally rare and only considered in highly selected patients with isolated cardiac and renal involvement and complete hematologic remission. Surgical debulking or amyloid-directed procedures have no established efficacy and are not performed.

Treatment advantages in China reflect rapid integration of global standards with unique infrastructural and pharmacoeconomic strengths. Major academic centers—including Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—offer comprehensive amyloidosis programs with on-site mass spectrometry for definitive amyloid typing, rapid-turnaround bone marrow and fat pad biopsies, and multidisciplinary tumor boards. Daratumumab and bortezomib are now included in China’s National Reimbursement Drug List (NRDL), substantially reducing out-of-pocket costs. Domestic biosimilars (e.g., bortezomib biosimilars approved by NMPA) further improve accessibility. Moreover, China’s centralized electronic health records and national amyloidosis registry facilitate longitudinal outcome tracking and real-world evidence generation. Clinical trial participation is robust, with Chinese sites enrolling heavily in global phase III studies (e.g., ANDROMEDA, APOLLO-B), accelerating access to novel therapies. Importantly, traditional Chinese medicine (TCM) adjuncts—such as Huangqi (Astragalus membranaceus) formulations—are sometimes integrated under nephrologist supervision for symptom palliation (e.g., fatigue, edema), though rigorous evidence for disease-modifying effects remains lacking and TCM use must never delay or replace evidence-based anti-plasma cell therapy.

Recovery and long-term follow-up require structured, lifelong monitoring. Patients should undergo hematologic assessment (serum free light chain assay, immunofixation, bone marrow biopsy if indicated) every 3 months for the first year, then quarterly for two years, and biannually thereafter if stable. Renal monitoring includes 24-hour urine protein, serum creatinine/eGFR, and albumin every 1–3 months initially. Echocardiography and NT-proBNP are mandatory for cardiac surveillance, even in asymptomatic patients. Vaccination against pneumococcus, influenza, and SARS-CoV-2 is strongly recommended due to inherent immune dysfunction and treatment-related immunosuppression. Psychosocial support—including counseling and patient advocacy groups (e.g., China Amyloidosis Alliance)—is integral, given the chronic, unpredictable course and high symptom burden. Patients must be counseled to avoid NSAIDs (risk of acute kidney injury), herbal nephrotoxins (e.g., aristolochic acid-containing herbs), and unregulated supplements. Finally, pregnancy is strongly discouraged during active disease or within 12 months of completing cytotoxic therapy due to teratogenic risk and hemodynamic stress on compromised kidneys and heart.